Related Experiment Videos
Fluoxetine and the serotonin syndrome
1Division of Emergency Medicine, Emory University School of Medicine, Atlanta, Georgia.
Annals of Emergency Medicine
|November 1, 1994
Summary
A patient developed serotonin syndrome, a potentially dangerous condition, after starting fluoxetine, a serotonin reuptake inhibitor, shortly after stopping tranylcypromine, a monoamine oxidase inhibitor. This highlights critical drug interaction risks.
Area of Science:
- Neuroscience
- Clinical Pharmacology
- Toxicology
Background:
- Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonergic activity in the central nervous system.
- Monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitors (SSRIs) are classes of drugs that affect serotonin levels.
- Abruptly stopping MAOIs and initiating SSRIs can increase the risk of adverse drug events.
Observation:
- A 48-year-old male presented with confusion, agitation, diaphoresis, and muscle rigidity.
- These symptoms emerged shortly after initiating fluoxetine (an SSRI).
- The patient had discontinued tranylcypromine (an MAOI) two weeks prior to presentation.
Findings:
- The clinical presentation was consistent with serotonin syndrome.
- The timing of symptom onset relative to medication changes strongly suggested a drug-induced etiology.
- The interaction between the MAOI withdrawal and SSRI initiation was implicated.
Implications:
- Highlights the critical importance of careful medication management and washout periods when switching between serotonergic agents.
- Underscores the need for clinician awareness regarding potential drug-drug interactions between MAOIs and SSRIs.
- Emphasizes prompt recognition and management of serotonin syndrome to prevent severe complications.